Genocea Biosciences (GNCA) Cut to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of Genocea Biosciences (NASDAQ:GNCA) from a buy rating to a hold rating in a research note issued to investors on Tuesday.

According to Zacks, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. “

Separately, HC Wainwright set a $5.00 target price on shares of Genocea Biosciences and gave the company a buy rating in a research report on Thursday, August 2nd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $3.79.

Shares of Genocea Biosciences stock opened at $0.77 on Tuesday. Genocea Biosciences has a 1 year low of $0.49 and a 1 year high of $1.69. The company has a market cap of $67.54 million, a price-to-earnings ratio of -0.39 and a beta of 0.99. The company has a debt-to-equity ratio of 0.95, a current ratio of 6.84 and a quick ratio of 6.84.

Genocea Biosciences (NASDAQ:GNCA) last announced its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. Equities research analysts predict that Genocea Biosciences will post -0.47 earnings per share for the current fiscal year.

Institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System lifted its position in Genocea Biosciences by 166.6% during the first quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 78,469 shares during the last quarter. Schwab Charles Investment Management Inc. purchased a new position in shares of Genocea Biosciences during the first quarter worth approximately $177,000. LMR Partners LLP purchased a new position in shares of Genocea Biosciences during the second quarter worth approximately $175,000. GSA Capital Partners LLP raised its stake in shares of Genocea Biosciences by 266.9% during the first quarter. GSA Capital Partners LLP now owns 234,065 shares of the biotechnology company’s stock worth $246,000 after acquiring an additional 170,265 shares in the last quarter. Finally, DRW Securities LLC purchased a new position in shares of Genocea Biosciences during the second quarter worth approximately $205,000. Institutional investors and hedge funds own 60.23% of the company’s stock.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Featured Article: Initial Public Offering (IPO)

Get a free copy of the Zacks research report on Genocea Biosciences (GNCA)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply